Amy Baxter

With fewer side effects, the new wave of upcoming drugs could improve patient adherence, and the competition for a large projected market is getting fierce.

The final drug prices for Medicare’s negotiation program have been published, but pharma companies continue to push their legal strategies.

By rejecting the first MDMA therapy this month, the FDA signaled to the psychedelic drug field that the road to approval isn’t easy.

The deal, which targets metabolic diseases, is one of a few by Big Pharma to develop lncRNA therapies.

Legislation that passed the House of Representatives passed the Biosecure Act last week would forced U.S. biotechs to cut ties with five Chinese contract partners.

The FDA’s backlog of overseas drug manufacturer inspections is still mounting — and new drugs could be delayed as a result.

Biosimilar competition to aging blockbusters will erode a large chunk of the pharma giant’s top line over the next few years.

Small biotechs are making gains with AI drug development, and their advantages may help some push ahead without Big Pharma.

Despite the drug’s wide patient pool, Madrigal is taking a targeted approach with its first launch.

The two presidential candidates have developed diverging policies related to healthcare and pharma.